Donald Stablein, Peter G. Stock, Shirish Huprikar, Margaret V. Ragni, Lorna Dove, Michelle E. Roland, Emily A. Blumberg, Dushyantha Jayaweera, John J. Fung, Nicholas N. Nissen, Sander Florman, Burc Barin, Michael P. Curry, Valentina Stosor, Mark S. Sulkowski, Timothy L. Pruett, and Aruna Subramanian
Background & Aims Human immunodeficiency virus (HIV) infection accelerates liver disease progression in patients with hepatitis C virus (HCV) and could shorten survival of those awaiting liver transplants. The Model for End-Stage Liver Disease (MELD) score predicts mortality in HIV-negative transplant candidates, but its reliability has not been established in HIV-positive candidates. Methods We evaluated predictors of pretransplantation mortality in HIV-positive liver transplant candidates enrolled in the Solid Organ Transplantation in HIV: Multi-Site Study (HIVTR) matched 1:5 by age, sex, race, and HCV infection with HIV-negative controls from the United Network for Organ Sharing. Results Of 167 HIVTR candidates, 24 died (14.4%); this mortality rate was similar to that of controls (88/792, 11.1%, P = .30) with no significant difference in causes of mortality. A significantly lower proportion of HIVTR candidates (34.7%) underwent liver transplantation, compared with controls (47.6%, P = .003). In the combined cohort, baseline MELD score predicted pretransplantation mortality (hazard ratio [HR], 1.27; P P = .20). After controlling for pretransplantation CD4 + cell count and HIV RNA levels, the only significant predictor of mortality in the HIV-infected subjects was pretransplantation MELD score (HR, 1.2; P Conclusions Pretransplantation mortality characteristics are similar between HIV-positive and HIV-negative candidates. Although lower CD4 + cell counts and detectable levels of HIV RNA might be associated with a higher rate of pretransplantation mortality, baseline MELD score was the only significant independent predictor of pretransplantation mortality in HIV-infected liver transplant candidates.